Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746983/?tool=EBI |
| _version_ | 1811288745519874048 |
|---|---|
| author | Masanori Tokumoto Shin Tokunaga Shinji Asada Yuichi Endo Noriaki Kurita Masafumi Fukagawa Tadao Akizawa |
| author_facet | Masanori Tokumoto Shin Tokunaga Shinji Asada Yuichi Endo Noriaki Kurita Masafumi Fukagawa Tadao Akizawa |
| author_sort | Masanori Tokumoto |
| collection | DOAJ |
| description | The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels, and safety, in an evaluation period (week 28 to week 30) by stratifying the previous phase 3 data with the final evocalcet dosages (low 1–2 mg [131 patients], medium 3–4 mg [90 patients], high 5–8 mg [92 patients]), and identified pre-treatment patient characteristics predicting the use of higher final evocalcet dosages via univariate and multivariate logistic regression models. At the end of the study at week 30, the median serum iPTH level was higher and the achievement ratio for the target range of Japanese Society for Dialysis Therapy (60–240 pg/mL) was lower in the final high-dose subgroup (216 pg/mL and 58%, respectively) than in the other subgroups (low: 149 pg/mL and 79%; medium: 149 pg/mL and 73%, respectively). Among the three subgroups, the mean serum corrected Ca and P levels demonstrated similar trends, and similar ratio of patients achieved the target range (corrected Ca, 8.4–10 mg/dL; P, 3.5–6.0 mg/dL) from week 28 to week 30. No dose-dependent safety concerns were identified. Younger age, prior cinacalcet use, higher serum levels of iPTH and corrected Ca, procollagen type 1 N-terminal propeptide, intact fibroblast growth factor-23, and larger maximum parathyroid gland volume were significantly associated with final high-dose evocalcet (p < 0.05 in all cases). Patients requiring final high-dose evocalcet had pre-treatment characteristics indicating severe SHPT, leading to a lower final achievement rate for the target PTH levels of Japanese Society for Dialysis Therapy. Therefore, the early initiation of evocalcet treatment for SHPT is critical. Trial registration: This trial was registered as follows: ClinicalTrials.gov: NCT02549391 and JAPIC: JapicCTI-153013. |
| first_indexed | 2024-04-13T03:42:37Z |
| format | Article |
| id | doaj.art-7220678bf596497c990edd686461160d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T03:42:37Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7220678bf596497c990edd686461160d2022-12-22T03:04:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011712Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidismMasanori TokumotoShin TokunagaShinji AsadaYuichi EndoNoriaki KuritaMasafumi FukagawaTadao AkizawaThe dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels, and safety, in an evaluation period (week 28 to week 30) by stratifying the previous phase 3 data with the final evocalcet dosages (low 1–2 mg [131 patients], medium 3–4 mg [90 patients], high 5–8 mg [92 patients]), and identified pre-treatment patient characteristics predicting the use of higher final evocalcet dosages via univariate and multivariate logistic regression models. At the end of the study at week 30, the median serum iPTH level was higher and the achievement ratio for the target range of Japanese Society for Dialysis Therapy (60–240 pg/mL) was lower in the final high-dose subgroup (216 pg/mL and 58%, respectively) than in the other subgroups (low: 149 pg/mL and 79%; medium: 149 pg/mL and 73%, respectively). Among the three subgroups, the mean serum corrected Ca and P levels demonstrated similar trends, and similar ratio of patients achieved the target range (corrected Ca, 8.4–10 mg/dL; P, 3.5–6.0 mg/dL) from week 28 to week 30. No dose-dependent safety concerns were identified. Younger age, prior cinacalcet use, higher serum levels of iPTH and corrected Ca, procollagen type 1 N-terminal propeptide, intact fibroblast growth factor-23, and larger maximum parathyroid gland volume were significantly associated with final high-dose evocalcet (p < 0.05 in all cases). Patients requiring final high-dose evocalcet had pre-treatment characteristics indicating severe SHPT, leading to a lower final achievement rate for the target PTH levels of Japanese Society for Dialysis Therapy. Therefore, the early initiation of evocalcet treatment for SHPT is critical. Trial registration: This trial was registered as follows: ClinicalTrials.gov: NCT02549391 and JAPIC: JapicCTI-153013.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746983/?tool=EBI |
| spellingShingle | Masanori Tokumoto Shin Tokunaga Shinji Asada Yuichi Endo Noriaki Kurita Masafumi Fukagawa Tadao Akizawa Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism PLoS ONE |
| title | Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_full | Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_fullStr | Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_full_unstemmed | Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_short | Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism |
| title_sort | predictive factors requiring high dose evocalcet in hemodialysis patients with secondary hyperparathyroidism |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746983/?tool=EBI |
| work_keys_str_mv | AT masanoritokumoto predictivefactorsrequiringhighdoseevocalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT shintokunaga predictivefactorsrequiringhighdoseevocalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT shinjiasada predictivefactorsrequiringhighdoseevocalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT yuichiendo predictivefactorsrequiringhighdoseevocalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT noriakikurita predictivefactorsrequiringhighdoseevocalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT masafumifukagawa predictivefactorsrequiringhighdoseevocalcetinhemodialysispatientswithsecondaryhyperparathyroidism AT tadaoakizawa predictivefactorsrequiringhighdoseevocalcetinhemodialysispatientswithsecondaryhyperparathyroidism |